NCT03382873

Brief Summary

The purpose of the study was to evaluate the impact of augmented care at the worksite through a lifestyle intervention for diabetes prevention among employees with prediabetes who were slower to respond to a standard diabetes prevention intervention.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
208

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 19, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 26, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

February 8, 2018

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2022

Completed
2 years until next milestone

Results Posted

Study results publicly available

April 11, 2024

Completed
Last Updated

April 11, 2024

Status Verified

March 1, 2024

Enrollment Period

4.2 years

First QC Date

December 19, 2017

Results QC Date

February 9, 2024

Last Update Submit

March 15, 2024

Conditions

Keywords

HyperglycemiaObeseOverweight

Outcome Measures

Primary Outcomes (3)

  • Percent Weight Change

    Change in weight as measured in light clothing and shoes removed

    baseline and 4-months

  • Percent Weight Change

    Change in weight as measured in light clothing and shoes removed

    baseline and 12-months

  • Percent Weight Change

    Change in weight as measured in light clothing and shoes removed

    12-months and 18-months

Secondary Outcomes (3)

  • Fasting Glucose

    baseline and 4-months

  • Fasting Glucose

    baseline and 12-months

  • Fasting Glucose

    12-months and 18-months

Study Arms (2)

Group Lifestyle Balance (GLB)

ACTIVE COMPARATOR

Standard lifestyle intervention to promote weight loss

Behavioral: Group Lifestyle Balance (GLB)

Group Lifestyle Balance Plus (GLB+)

EXPERIMENTAL

Augmented lifestyle intervention for early slow responders

Behavioral: Group Lifestyle Balance Plus (GLB+)

Interventions

The intervention included the following key features: group-based sessions led by a lifestyle coach; a structured, state-of-the-art, 16-session core-curriculum that emphasized behavioral self-management strategies for weight loss and physical activity; 8-months of extended care with bimonthly or monthly sessions; self-monitoring of diet and physical activity.

Group Lifestyle Balance (GLB)

The GLB+ intervention arm included participants who did not achieve the targeted percent weight loss by week 5 and incorporated enhanced training in values clarification, mindful decision making, planning, and problem solving. GLB+ included the same number of group-based sessions as GLB.

Group Lifestyle Balance Plus (GLB+)

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Benefits-eligible Ohio State University (OSU) employee
  • Intend to be employed by OSU through the length of the follow-up phase
  • Body mass index: \>24 kg/m\^2 non-Asians; \>22 kg/m\^2 Asians
  • Fasting blood glucose of 100-125 mg/dL or an A1c of 5.7-6.4%
  • Blood glucose of 110-199 (if non-fasting in previous 2 hours)

You may not qualify if:

  • Blood glucose level of ≥ 200 mg/dL
  • Conditions that would limit adoption of light/moderate physical activity (i.e., cardiac event, severe chronic obstructive pulmonary disease, advanced arthritis, poorly controlled hypertension)
  • Chronic use of medications that affect blood glucose levels (i.e., corticosteroids)
  • Concurrent participation in a structured weight loss program or counseling for bariatric surgery
  • Pregnant or breastfeeding
  • Score of ≥ 10 on the Patient Health Questionnaire-8 indicating moderate to severe depressive symptoms
  • Score of ≥ 27 on the Binge Eating Scale indicating the potential for binge eating
  • Unwilling to accept randomization
  • Planning to move from the area or changing employment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Ohio State University

Columbus, Ohio, 43210, United States

Location

Related Publications (3)

  • Miller CK, Nagaraja HN, Cheavens JS, Fujita K, Lazarus SA, Brunette DS. Sex Differences in Early Weight Loss Success During a Diabetes Prevention Intervention. Am J Health Behav. 2023 Apr 30;47(2):337-348. doi: 10.5993/AJHB.47.2.13.

  • Miller CK, King D, Nagaraja HN, Fujita K, Cheavens J, Focht BC. Impact of an augmented intervention on self-regulatory, dietary and physical activity outcomes in a diabetes prevention trial among adults with prediabetes. J Behav Med. 2023 Oct;46(5):770-780. doi: 10.1007/s10865-023-00406-w. Epub 2023 Mar 18.

  • Miller CK, Nagaraja HN, Cheavens J, Fujita K, Lazarus S. Impact of a Novel Diabetes Prevention Intervention for Early Slow Weight Loss Responders Among Adults With Prediabetes: An Adaptive Trial. Diabetes Care. 2022 Oct 1;45(10):2452-2455. doi: 10.2337/dc22-0824.

MeSH Terms

Conditions

Prediabetic StateHyperglycemiaObesityOverweight

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Limitations and Caveats

Four participant cohorts did not complete the 18-month visit due to pandemic-related restrictions during the SARS-CoV-2 pandemic. Thus, the 18-month outcomes include a smaller sample and should be interpreted with caution.

Results Point of Contact

Title
Dr. Carla Miller (current affiliation)
Organization
Indiana University

Study Officials

  • Carla Miller, Ph.D.

    The Ohio State University (during study implementation)

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: The proposed translational study applied an innovative experimental approach, an adaptive design, to optimize treatment for weight loss and weight loss maintenance in individuals with prediabetes. All participants initiated a standard lifestyle intervention to promote weight loss. Those who did not achieve \>2.5% weight loss during the first month of the intervention were stratified to augmented care to enhance weight loss during the intensive intervention phase. Following the intensive phase, participants were randomly assigned to either the standard intervention or the enhanced intervention for the maintenance study phase. By randomly assigning participants to either the standard maintenance phase of the intervention or the innovative maintenance phase of the intervention following the initial core phase, the impact of extended training in self-regulation for weight loss maintenance was evaluated.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor (current affiliation at Indiana University)

Study Record Dates

First Submitted

December 19, 2017

First Posted

December 26, 2017

Study Start

February 8, 2018

Primary Completion

April 15, 2022

Study Completion

April 15, 2022

Last Updated

April 11, 2024

Results First Posted

April 11, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will share

De-identified data will be released to other researchers using a data-sharing agreement that specifies that the data will be used only for research purposes and only by the specified individuals to whom the data are released. Documentation of Institutional Review Board approval for the proposed use must be provided in advance to the PI. The data must be either destroyed or returned to the PI after all analyses are completed.

Shared Documents
CSR
Time Frame
The data will be available following all analyses and publication of primary and secondary study results. The data will be available upon request.
Access Criteria
To be developed

Locations